BPMC stock raised to Buy at Jefferies on potential of rare disease therapy (NASDAQ:BPMC)
seekingalpha.com
finance
2022-06-01 16:31:39

Pgiam/iStock via Getty Images Jefferies has upgraded Blueprint Medicines (NASDAQ:BPMC) to Buy from Hold as the commercial-stage biotech prepares to report topline data for registration-enabling PIONEER trial for Ayvakit in non-advanced (Indolent) systemic mastocytosis (ISM) in late summer 2022. A rare genetically driven condition, systemic mastocytosis impacts patients' quality of life, with many suffering from the non-advanced form of the disease. Ayvakit, known as avapritinib in generic terms, is already approved in the U.
